Forward Science: The next chapter in pancreatic cancer research
Pankind Scientific Meeting 2026
Friday 30 October 2026, Swissotel, Sydney
Questions for speakers
Have a question for our speakers? Send it through Slido during each session and we’ll put it to them in the Q&A.
Michelle Stewart
Chief Executive Officer
Welcome from our CEO
Dear Guests,
On behalf of Pankind, Pancreatic Cancer Australia, it is my great pleasure to welcome you to our 2026 Scientific Meeting.
Last year's meeting, The Road to Treatment' showed a field at a turning point, with emerging KRAS inhibitors, precision diagnostics and the promise of earlier detection. This year's theme, Forward Science: The next chapter in pancreatic cancer research', asks where we go from here. The choices we make now, about which questions to pursue and how to carry discovery into care, will shape outcomes for years to come.
Read more
Those choices are best made together. Progress rarely comes from one lab working alone. It comes from a scientist hearing what a surgeon sees in theatre, or a collaboration that starts over coffee. Many ideas for the next chapter will begin here.
This year Pankind will make its highest ever investment in research. We seed fund bold, early-stage ideas so they can build the proof of concept to attract larger investment. We are also working to remove the barriers that slow research, focusing on bioresources, centres of excellence and surgical volume.
Our resource Living with Pancreatic Cancer is now joined by "When Surgery Is Not an Option". Our Support Navigation Program is growing, particularly in clinical trial navigation and risk pathways, and our new Carer Support Program offers structured counselling initially designed by Vanessa Beesley and Rachel Neale at QIMR Berghofer.
Understanding risk remains a priority. We support surveillance for people with a family history at the Jreissati Pancreatic Centre at Epworth Hospital and are building access to familial genomic testing. We also advocate for timely access to genomic profiling, clinical trials and new treatments. Discovery only changes lives when it reaches people.
We are especially proud that our Head of Research, Amber Johns, has been a critical part of the Lancet Oncology Commission on Accelerating Equitable Cancer Genomics and Precision Oncology, a landmark global initiative working to make genomics and precision oncology accessible to everyone with cancer.
Our mission is bold: to triple pancreatic cancer survival by 2030. We will not get there alone, and we do not have to.
During this meeting, I encourage you to ask the hard questions, share the unfinished idea and leave with at least one new connection. That is how the next chapter gets written.
Thank you for your passion, persistence and partnership. Your work gives hope to every person and family affected by pancreatic cancer.
With best wishes,
Michelle Stewart
Chief Executive Officer
2026 Program
8:30 - 8.50
Arrival and poster set up
9:00
Welcome and introductions
Michelle Stewart, CEO
9:10–10:30
Plenary Session
Chair: Amber Johns
Dr Wungki Park
GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, USA
Pancreatic Cancer: From Biology to Breakthroughs
Prof David Chang
Chair of Surgical Oncology, University of Glasgow, UK
Pancreatic Cancer: From Pixel to Patient
10:30–11:10
Morning tea and posters
11:10–12:10
Session 1: New Treatments and Targeted Therapies
Chair: Chris Baggoley
Dr Mark Adams, QUT
Restoring Chemotherapy Sensitivity by Targeting a Novel Driver of Resistance in Pancreatic Cancer
Prof John Hooper, University of Queensland
Illuminating and Eliminating - Payloaded Antibodies for Pancreatic Cancer Detection and Therapy
12:10–12:55
Session 2: Panel Discussion
Accelerating the Pipeline: What Will It Take to Move Faster?
Moderator: Steve Robson
12:55–14:25
Lunch break / Poster walkaround
14:25–15:25
Session 3: Early Detection
Dr Chamini Perera, UNSW
Deciphering the Exosomal RNA Cargo Involved in Pancreatic Cancer-Related Diabetes
Dr Michaela Kindlova, University of Queensland
Beyond the sequence: Elucidation of epigenetic drift in pancreatic cancer
Prof Andrew Metz, Epworth HealthCare
Pancreatic cancer surveillance and the APRISE program
15:25–16:00
Session 4: Moderated Group Discussion
Moderator: Amber Johns
This session picks up where the day’s talks leave off. We’ll ask you for
the one priority, or big-ticket item, you’d back to move pancreatic cancer
research forward in Australia. We’ll also return to questions from the
panel and earlier sessions that ran out of time. The aim is a practical
answer to one question: how can we work better together?
16:00–16:20
Afternoon tea
16:20–16:35
Award Presentations
Chair: Ross McKinnon
Poster Prize
Most outstanding presentation, as judged by the Scientific Committee
Pankind Research Impact Award
Scientific excellence and the real-world difference that research can make to patients and their families
16:35–16:45
Closing Remarks
17:00–19:00
Networking Drinks
Ten Stories Upper Deck Bar (Level 8)
Plenary session speakers
We're thrilled to welcome two global leaders to our plenary session: Dr. Wungki Park from Memorial Sloan Kettering Cancer Center, New York, and Professor David Chang, the Chair of Surgical Oncology at the University of Glasgow.
Dr Wungki Park
Dr Wungki Park is a GI medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center specialising in pancreatic and biliary cancers, with a research program focused on first-in-human novel KRAS-directed therapies, DNA damage repair biology, and immune modulation.
Read more
He leads multiple investigator-initiated and industry clinical trials. His lab (sPARK lab) integrates genomics, single-cell, spatial and computational data analysis to define tumor evolution, cachexia mechanisms, and therapeutic vulnerabilities, and uses AI-technologies for early detection and pathology biomarkers for treatments in pancreatic cancer.
He is a founder of GRIT (GI RAS Innovative Therapeutics), and this initiative focuses on translational science and developmental therapeutics for RAS-driven GI cancers. He is deeply committed to mentoring the next generation of physician–scientists and advancing innovative, patient-centered approaches to improve outcomes in these historically lethal cancers.
Professor David Chang
Professor David Chang holds the Chair of Surgical Oncology at the University of Glasgow. His research focuses on a better understanding of the molecular pathology of pancreatic cancer to inform novel therapeutic strategies.
Read more
Professor Chang undertook his HPB and Upper GI Surgery fellowship, PhD, and post-doctoral training in Australia. He was recruited to the University of Glasgow in 2013 as part of the research initiative for precision medicine in Scotland.
He leads Precision-Panc, a UK national therapeutic development platform to deliver personalised cancer care for pancreatic cancer. Professor Chang is also the UK lead of the European Horizon H2020-funded pancreatic cancer AI consortium, PANCAIM, which aims to develop AI and machine learning applications to better understand pancreatic cancer molecular pathology and treatment for patients. He also took up the Chair of the UK National Pancreatic Cancer Research Group in 2025, driving the national pancreatic cancer clinical research priorities.
Session speakers
Dr Mark Adams
Senior Research Fellow at the Queensland University of Technology
Dr Mark Adams is a Senior Research Fellow at the Queensland University of Technology (QUT). He completed his PhD at the Mater Research Institute–The University of Queensland in 2012 and, supported by an NHMRC Early Career Fellowship, undertook postdoctoral training at the Translational Research Institute (TRI) on the Princess Alexandra Hospital campus. Dr Adams is now based at QUT’s Kelvin Grove campus, where he leads a research program focused on exploiting cellular programmes that regulate genome instability, cell cycle control, and cell growth.
His work aims to identify novel therapeutic vulnerabilities and improve treatment responses in the deadliest solid cancers, particularly pancreatic and lung cancers. His research has been published in leading international journals, including Journal of Thoracic Oncology, Nature Communications, and Nucleic Acids Research, and has attracted competitive funding from the Queensland Government, the NHMRC, the International Lung Cancer Foundation, Cancer Australia, Cure Cancer, Tour de Cure, and Pankind.
Marina Pajic
University of Sydney
Professor Marina Pajic is a leader in pancreatic cancer research. Since returning from a successful postdoctoral position at the Netherlands Cancer Institute and establishing her lab at the Garvan in 2013, Professor Pajic has developed an innovative program that builds on the unique infrastructure she has generated, a wealth of integrated human cancer genomic and gene product expression profiles, complex 3D and patient-derived mouse models, rapidly evolving technologies and close clinical links, to reveal new insights into the deregulation of molecules commonly hijacked in pancreatic cancer, which drive tumour heterogeneity, metastasis and chemoresistance. Her team is using this knowledge to inform the rational design of novel, tailored treatment options for patients with pancreatic cancer. In 2026, Prof Pajic was appointed as the Paul and Katherine Gobits (Koh) Chair of Pancreatic Cancer Research at the University of Sydney. In this role she will bring together scientists, clinicians and emerging researchers to accelerate discoveries, develop better treatments and ultimately give more people with pancreatic cancer the chance to live longer, healthier lives.
Her research is supported by the Snow Medical Fellowship, NHMRC, Cancer Council NSW, ACRF and Cancer Institute NSW (CINSW). As a Snow Medical Fellow, Professor Pajic has established a translational precision oncology program, which will include establishment of two new trials for pancreatic cancer, based on precision-medicine principles and her discovery work, during the fellowship. With more than 90 high-quality and highly cited publications in the field (more than 25,500 citations), Professor Pajic’s contributions have been recognised by several prestigious awards including the Australian Academy of Science 2020 Ruth Stephens Gani Medal for achievements in the field of applied cancer genomics and precision medicine for pancreatic cancer and the NSW Premier’s Outstanding Cancer Research Fellow Award.
Professor John Hooper
Mater Research Institute, The University of Queensland
Professor John Hooper leads the Cancer Biology Lab at the Mater Research Institute, The University of Queensland, where his team is investigating better ways to detect and treat a range of cancers, particularly pancreatic cancer. His team is developing new agents for fluorescence-guided surgery, PET/CT imaging, antibody-drug conjugates, and theranostics. One of the PET/CT imaging agents developed by his lab is currently being tested in phase 1 clinical trials in pancreatic cancer patients, as well as bladder, breast, and ovarian cancer patients.
Dr Chamini Perera
UNSW Sydney
Dr Chamini Perera is a Senior Lecturer at UNSW Sydney and an emerging leader in pancreatic cancer research. Her work focuses on biomarker discovery for the early detection of pancreatic
cancer. She completed her PhD in Neuroscience in 2016 and now leads the Pancreatic Cancer‑Related Diabetes Program at the South Western Sydney Clinical Campuses, UNSW/Ingham Institute, with a particular focus on identifying novel biomarkers in exosomes derived from pancreatic cancer-stromal interactions. Chamini serves as the Honorary Secretary of the Australasian Pancreatic Club and is committed to mentoring early‑career researchers and higher‑degree research students.
Dr Michaela Kindlova
Mater Research, Translational Bioinformatics Group
Dr Michaela Kindlova is a senior research officer within the Translational Bioinformatics Group at Mater Research (Brisbane). In 2013, she was awarded a PhD in parasitology (Charles University, Prague). After that, she succeeded in highly prestigious Group of 8 European fellowship program which brought her to Australia. During her half year-long stay at University of Queensland, she transitioned to the field of molecular biology. Her interest shifted from parasitic diseases to disorders caused by genomic and epigenomic aberrations including the major threat, cancer.
Despite several career disruptions, Dr Kindlova is currently building a path of an emerging leader at Mater Research. Her main goal is to understand the pancreatic and prostatic cancer milieu, particularly the genomic and epigenomic processes initiating carcinogenesis and the use of epigenetic markers such as methylation in their early detection. Her recent work published in Nature Communications (2025 Nov 24;16:10358) employed innovative Oxford nanopore sequencing and bioinformatical analysis utilising their own software published in Bioinformatics (2022 May 26;38(11):3109-3112). Michaela’s work on Pancreatic cancer has recently been funded through a TRI LINC Grant (2024), a Mater Research EMCR seeding grant (2025) and a Pankind Early Detection Grant (2025), which have opened the door for exploring novel strategies for early detection as well as treatment.
Professor Andrew Metz
Jreissati Pancreatic Centre at Epworth
Andrew Metz is a gastroenterologist and Head of Endoscopy at the Royal Melbourne Hospital, having previously been Head of Endoscopy at Cambridge University Hospital UK. He has an interest in pancreatic disease, running a multi-disciplinary clinic for all pancreatic conditions. He is the Inaugural Director of the Jreissati Pancreatic Centre, is the treasurer of the Australasian Pancreatic Club, and a council member of the International Association of Pancreatology. His research interests include early detection and screening of pancreatic cancer, as well as novel endoscopic devices for therapy.
Panel discussion
Accelerating the Pipeline: What Will It Take to Move Faster?
New targets and a wave of RAS-targeted therapies are changing what is possible in pancreatic cancer. Our panel asks what it will take to move faster. Join the conversation on the barriers that slow progress, and the practical changes that could shorten the path from discovery to the clinic.
Steve Robson
Panel discussion chair
Clinician and surgeon, author and leader in health policy
Steve Robson is one of Australia’s foremost advocates for, and leaders in, health and health policy. He has been a practicing doctor for 35 years. Steve is a Professor of Obstetrics and Gynaecology at the Australian National University Medical School with special training and expertise in reproductive medicine, genetics, and pelvic surgery. He has authored hundreds of articles, papers, and textbooks – both in medicine and economics. Steve is currently President of the Australian Medical Association. He has served as President of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
His family has a significant history of pancreatic cancer, with five of his father’s eight siblings lost to the disease. Steve brings a personal understanding of the importance of early detection and awareness and we are pleased to welcome him as Chair of the panel discussion.
Poster abstracts
We encourage you to explore the research posters on display and discover more of the exciting work being undertaken across the pancreatic cancer research community.
A large molecular model of cancer harmonizes bioprinted PDAC co-cultures with patient biology
Principal Investigator: Joe Gillson
Institution: Inventia Life Science
68Ga-FAPI-46 PET/CT Versus 18F-FDG PET/CT for Pancreatic Cancer: A Feasibility Study
Principal Investigator: Yvette Coulon
Institution: I-Med Radiology
Enhancing the efficacy of and overcoming resistance to Kras Inhibitors in Pancreatic Cancer
Principal Investigator: Niahm Mills
Institution: Garvan
Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq
Principal Investigator: Michael Trpceski
Institution: Garvan
Development of an immune-humanised mouse model for pancreatic cancer research
Principal Investigator: Diana Schumacher
Institution: Garvan
High-throughput plasma affinity proteomic profiling identifies a candidate biomarker to improve early-stage pancreatic ductal adenocarcinoma detection
Principal Investigator: Stellene Vitaro
Institution: Flinders
Therapeutic potential of co-targeting PRMT5 and MAT2A in MTAP-loss pancreatic cancer
Principal Investigator: Johana Luhur
Institution: Garvan
Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Principal Investigator: David Herrmann
Institution: Garvan
The Australian Pancreatic High-RIsk ScrEening (APRISE) Program
Principal Investigator: Halina Pietrzak
Institution: Jreissati Centre, Epworth
Primary cancer associated fibroblasts alter PDAC tumour organoid subtype through epigenetic regulation
Principal Investigator: Emilie Jaune
Institution: Frazer Institute, University of Queensland
Co-targeting thrombospondin-1 (THBS-1) to improve KRAS inhibitor efficacy in pancreatic cancer
Principal Investigator: Victoria Tyma
Institution: Garvan
Targeting Pain Pathways in Pancreatic Cancer: Validation of CXCL12-CXCR4 Axis
Principal Investigator: Joseph Cheung
Institution: Ingham Institute
Defining and Evaluating Lithium as a Modulator of the Tumour Immune Microenvironment in difficult to treat tumours
Principal Investigator: Jessica Jenner
Institution: Garvan Institute
Hunting Hidden Tumours: Nanobots for wireless detection of Pancreatic Cancer
Principal Investigator: William Louis
Institution: RMIT
The Effect of Nutrient Availability and KRAS Mutations on Daraxonrasib Treatment in PDAC Cell Lines
Principal Investigator: Justin Moon
Institution: Victor Chang
Large-scale pharmacotranscriptomics maps genotype- and cell-state-specific drug responses in pancreatic cancer
Principal Investigator: Daksh Pamar
Institution: Melbourne University
PemOla: A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden ≥ 4 mutations/Mb
Principal Investigator: Sandra Hayes
Institution: GI Cancer Trials
Stromal precision targeting sensitizes mouse pancreatic cancer to immune checkpoint inhibition
Principal Investigator: Bo He
Institution: Harry Perkins Institute of Medical Research
Nanomotors for the early detection of Pancreatic Ductal Adenocarcinoma
Principal Investigator: Srikrishnan Ramachandran
Institution: Deakin University
Research grant recipients
Early Detection Innovation
Funds innovation research to improve early detection and diagnosis of pancreatic cancer by supporting feasibility and proof-of-concept studies.
Improving early detection of pancreatic cancer by exploring the faulty methylation of pre-cancerous tissue
Principal Investigator: Michaela Kindlova
Seeing the unseen: a targeted fluorescent probe to detect otherwise invisible pre-cancerous lesions in the pancreas
Principal Investigator: William McGahan
Simultaneous targeted methylome and genome sequencing from early-stage pancreatic cancer as a sensitive, multi-factor liquid biopsy
Principal Investigator: Orion Tong
Pancreatic Cancer-Related Diabetes: A Critical Juncture for Pancreatic Cancer Detection
Principal Investigator: Chamini Perera
Metabolism-Driven Biomarker Discovery for Early Detection of PDAC
Principal Investigator: Nils Halberg
New Treatment Innovation
Supports early-stage research to develop new treatments, diagnostics, or quality-of-care improvements for pancreatic cancer.
Starving the Enemy: Undermining CAF-Driven Metabolic Support in PDAC to Reawaken Immune Defence
Principal Investigator: Zaklina Kovacevic
Exploiting Shared Cancer Antigens for Off-the-Shelf Immunotherapy in Pancreatic Cancer
Principal Investigator: Pouya Faridi
Unlocking Synergy: Drug Combinations Targeting Critical Survival Factors for Enhanced Therapeutic Efficacy in Pancreatic Cancer
Principal Investigator: Walter Fairlie
Targeting lipid desaturase activity to enhance chemotherapy response in pancreatic cancer
Principal Investigator: Sarah Hancock
Augmenting a novel mechanism to restore pancreatic cancer response to treatment
Principal Investigator: Mark Adams
New Treatment Accelerator
Funds advanced research to fast-track new treatments from the lab to clinical application, driving real-world impact.
Developing the Next-Generation T Cell Therapy for Pancreatic Cancer via Precision Genome Editing
Principal Investigator: Isabelle Munoz
Selective inhibition of integrin signalling as a novel precision medicine approach: targeting treatment resistance in pancreatic cancer
Principal Investigator: Marina Pajic
Novel antibody-based drugs to target pancreatic tumours
Principal Investigator: Peter Janes
Panc-PET - a molecular-imaging trial to guide targeted therapy for pancreatic cancer
Principal Investigator: John Hooper
DISCOVERY-P: Adaptive study evaluating new therapies in early-stage pancreatic cancer utilising circulating tumour DNA (ctDNA) to guide adjuvant therapy selection
Principal Investigator: Belinda Lee
2024 Early Detection Innovation Grants
Development of a non-invasive urine screening test to identify patients with early pancreatic cancer (Marianne Allan Pancreatic Cancer Research Grant)
Principal Investigator: Belinda Lee
Institute: Walter and Eliza Hall Institute of Medical Research
Single extracellular vesicle analysis to identify high-risk pancreatic cancer precursor lesions
Principal Investigator: Ying Zhu
Institute: University of Technology Sydney
Exploring the plasma proteome to find biomarkers that can detect early-stage pancreatic ductal adenocarcinoma
Principal Investigator: Jean Winter
Institute: Flinders University
2024 New Treatment Grants
Enhancing the efficacy of and overcoming resistance to Kras Inhibitors in Pancreatic Cancer
Principal Investigator: Kendelle Murphy
Institute: Garvan Institute of Medical Research
Targeting fibrosis to improve clinical KRAS G12D inhibitor MRTX1133 efficacy in pancreatic cancer
Principal Investigator: Brooke Pereira
Institute: Garvan Institute of Medical Research
Novel radiopharmaceutical therapies targeting tumour stroma for treating pancreatic cancer
Principal Investigator: Andrew Scott
Institute: Olivia Newton-John Cancer Research Institute
Advancing a new targeted antibody to combat pancreatic cancer
Principal Investigator: Claudine Bonder
Institute: University of South Australia
2023 Early Detection Innovation Grant (Marianne Allan Pancreatic Cancer Research Grant)
Development of a blood based test to identify patients with early pancreatic cancer.
Principal Investigator: Dr Belinda Lee
Institute: Walter and Eliza Hall Institute of Medical Research
2023 New Treatment Grants
Receptor-directed precision medicines for pancreatic cancer
Principal Investigator: Prof John Hooper
Institute: Royal Brisbane and Women's Hospital
PemOla: A phase II study combining pembrolizumab and olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Principal Investigator: Dr Daniel Croagh
Institute: Australian Gastro Intestinal Trials Group
Targeting oncogenic Pol-II transcription cycles using cyclin-dependent-kinase inhibitors: a new therapeutic approach for pancreatic cancer
Principal Investigator: Prof Ricky Johnstone
Institute: University of Melbourne
Targeting lymph-pancreas interactions to treat pancreatic cancer
Principal Investigator: Dr Enyuan Cao
Institute: Monash University
New pancreatic cancer treatment involving Aryl Hydrocarbon Receptor (AhR) inhibition in the tumour and microenvironment
Principal Investigator: A/Prof Jennette Sakoff
Institute: Calvary Mater Newcastle
Polymer mimics of the TRAIL protein for pancreatic cancer
Principal Investigator: Dr Robert Chapman
Institute: The University of Newcastle
2022 Early Detection Innovation Grants
Lighting up the needle in the haystack: targeting malignant stroma to detect early pancreatic cancer on PET.
Principal Investigator: A/Prof David Cavallucci
Institute: Royal Brisbane and Women's Hospital
Development of an early detection biomarker for pancreatic cancer.
Principal Investigator: A/Prof Jason Lee
Institute: QIMR Berghofer Medical Research Institute
A blood test for early detection of pancreatic cancer by single extracellular vesicle analysis.
Principal Investigator: Dr Ying Zhu
Institute: University of Technology Sydney
Identifying metabolic changes in pancreatic fibroblasts during development of pancreatic cancer to facilitate early detection.
Principal Investigator: Dr Zaklina Kovacevic
Institute: The University of Sydney
2022 New Treatment Accelerator Grants
Trapping pancreatic cancer in a crossfire: investigating a combination treatment approach designed to eradicate pancreatic cancer.
Principal Investigator: Dr Alex Staudacher and Dr Vasilios Liapis
Institute: Central Adelaide Local Health Network
Targeting epigenetic modifying enzymes as a novel therapy for pancreatic cancer.
Principal Investigator: A/Prof Jason Lee
Institute: QIMR Berghofer Medical Research Institute
Advanced analysis of lipid metabolism in pancreatic cancer to reveal new therapeutic targets
Principal Investigator: Prof Nigel Turner
Institute: Victor Chang Cardiac Research Institute
Using precision medicine approaches in pancreatic cancer to improve chemosensitivity via porcupine inhibition.
Principal Investigator: Dr Sean Porazinski
Institute: Garvan Institute of Medical Research
2021 Early Detection Innovation Grants
1Development of Biomarker Tests for Early Detection/Diagnosis of Pancreatic Cancer.
Principal Investigator: Prof Anubhav Mittal
Institute: The University of Sydney
Advancing a novel ‘early detection’ biomarker for PDAC.
Principal Investigator: Prof Claudine Bonder
Institute: Centre for Cancer Biology
Deciphering the Exosomal RNA Cargo in Pancreatic Cancer-related diabetes using Transcriptmonics: A Novel Approach for Early Detection of Pancreatic Cancer
Principal Investigator: Dr Chamini Perera
Institute: The University of New South Wales
Early Detection and Diagnosis of Pancreatic Cancer using Circulating Tumour Cells.
Principal Investigator: Prof John Rasko
Institute: The University of Sydney
Can the molecules carried by exosomes help to diagnose pancreatic cancer early?
Principal Investigator: Prof Marco Falasca
Institute: Curtin University
2021 New Treatment Accelerator Grants
3D Human Tumour Explant Culture to Inform Precision Medicine in Pancreatic Cancer.
Principal Investigator: Dr George Sharbeen
Institute: The University of New South Wales
Spatial Transcriptomics a Pathway to Dissecting Barriers to Effective Treatment in Pancreatic Cancer.
Principal Investigator: Prof Phoebe Phillips
Institute: The University of New South Wales
Repurposing FDA/TGA-approved PCSK9 inhibitor evolocumab to enhance immunotherapy outcomes in pancreatic cancer.
Principal Investigator: Prof Paul Timpson and Dr Brooke Pereira
Institute: Garvan Institute of Medical Research
Pankind offers a range of competitive and strategic funding opportunities throughout the year, ensuring researchers have access to the resources needed to accelerate scientific advancements.

Every week matters
For people living with pancreatic cancer, time is precious. Through our Every Week Matters campaign, we’re advocating for faster, more flexible pathways to access new medicines, so promising treatments can reach people sooner.
Add your voice and help us make the case for change.
Pankind patient and carer resources
Pankind supports people impacted by pancreatic cancer by providing relevant information, valuable resources and a connection to others affected by the disease.
We encourage you to share our resource pages with any patient, carer or community members you connect with. Our resources are provided free of charge on both soft and hard copies. You can also email info@pankind.org.au for any additional patient or support related enquiries.
Thank you to our sponsors
Pankind, Pancreatic Cancer Australia, respectfully acknowledges the Gadigal people of the Eora nation as the Traditional Custodians of this land on which we meet today. We would also like to pay our respects to Elders past, present and emerging.